Skip to main
COLL

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical Inc. is poised for strong growth, primarily driven by its successful product, Jornay PM, which has demonstrated a remarkable 19% year-over-year revenue increase, reaching $42 million, and capturing a market share of 23.4%. The company’s recent expansion of its sales force and focused digital marketing efforts are expected to bolster education and awareness among prescribers and patients, further supporting sales growth. Additionally, expected improvements in gross-to-net (GTN) ratios and a robust outlook for script growth in the adult segment position Collegium favorably for continued top-line performance in the upcoming years.

Bears say

Collegium Pharmaceutical Inc. faces significant risks that contribute to a negative outlook for its stock, primarily stemming from expected declines in sales from key products including Xtampza ER and the Nucynta franchise, as well as potential early generic competition for multiple offerings. The company's 2026 sales guidance reflects a decrease to approximately $620 million for its pain portfolio, indicating a slowdown from previous sales estimates. Additionally, risks surrounding commercialization, including supply chain issues and unfavorable reimbursement dynamics, could further hinder profitability and growth prospects.

Collegium Pharmaceutical (COLL) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Buy based on their latest research and market trends.

According to 5 analysts, Collegium Pharmaceutical (COLL) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.